---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-266704"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2023-10-31T23:59:59+00:00"
generated_at: "2026-06-09T04:39:18.575299+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Galera: FDA demands new Phase 3 for avasopasem; GRECO-2 futility halts both rucosopasem trials

## Summary
- FDA reiterated need for an additional Phase 3 trial of avasopasem for radiotherapy-induced SOM.
- GRECO-2 futility analysis (35 deaths, 177 enrolled) led to discontinuation of both GRECO-1 and GRECO-2 trials.
- Preliminary cash, cash equivalents & short-term investments: $28.4M as of Sep 30, 2023.
- Engaged Stifel to review strategic alternatives (merger, sale, licensing); may cease operations if none found.
- Company assessing strategic options to maximize shareholder value; going concern risk noted.

## SEC filing metadata
- accession: 0001193125-23-266704
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2023-10-31T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312523266704/0001193125-23-266704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312523266704/d568178d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-266704
- JSON: https://secwatch.observer/filing/0001193125-23-266704.json
- Plain text: https://secwatch.observer/filing/0001193125-23-266704.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.